Precision oncology startup 4baseCare has successfully closed a funding round of Rs 128 crore after securing an additional Rs 38 crore in a top-up investment led by growX Ventures and Infosys. Existing investors also participated in the round, further strengthening confidence in the company’s vision of making precision cancer care more accessible across emerging markets.
The Bengaluru-based healthtech startup had previously raised Rs 90 crore from investors Ashish Kacholia, Lashit Sanghvi, and existing backer Yali Capital. With the latest infusion of capital, 4baseCare plans to accelerate the global expansion of its genomics laboratory network while scaling its artificial intelligence-driven oncology platform, OncoTwin.
Speaking about the company’s vision, Hitesh Goswami, Co-founder and Chief Executive Officer of 4baseCare, said, “We want precision oncology globally to be more inclusive. Most genomic datasets, drug discovery, and clinical trials are still heavily concentrated in the US and Europe. We are building solutions for underrepresented populations across India, the Middle East, Southeast Asia, and Latin America.”
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare specializes in genomics-based cancer diagnostics and AI-powered clinical decision support solutions. The company focuses on addressing the lack of population-specific genomic data, enabling healthcare providers to deliver more personalized and effective cancer treatments.
Currently, the startup operates laboratories in India, Dubai, Nepal, and the Philippines. Over the next 12 to 18 months, the company plans to expand its presence into eight to ten additional countries, strengthening its international footprint in the precision medicine sector.
Alongside its global expansion strategy, 4baseCare is also decentralizing genomic testing infrastructure across India. Instead of relying solely on centralized testing facilities, the company has partnered with leading healthcare institutions, including Max Healthcare, AIIMS Jammu, and Shankara Hospital, to establish genomics laboratories within hospitals.
Explaining the strategy, Goswami said, “Rather than having all samples shipped to Bengaluru, we are taking the technology closer to patients and doctors. That improves turnaround time, improves research collaboration, and makes advanced cancer diagnostics more accessible.”
The company currently operates four active genomics laboratories in India and conducts approximately 1,500 genomic tests every month. According to Co-founder Kshitij Rishi, the planned expansion could increase testing volumes to between 8,000 and 10,000 tests per month.
India records nearly 15 lakh new cancer cases annually, with approximately 70% of patients receiving diagnoses at advanced stages. At these stages, targeted therapies and immunotherapies often become critical treatment options. Genomic testing plays a key role in identifying molecular changes within tumors and matching patients with more personalized treatment pathways.
Highlighting the transformation in cancer care, Rishi said, “Earlier, cancer treatment was mostly chemotherapy. Now it is becoming far more targeted through genomics, biomarkers, and immunotherapy.”
The company has also witnessed growing adoption of genomic testing beyond metropolitan hospitals. According to 4baseCare, patients from tier 2 and tier 3 cities increasingly seek advanced cancer diagnostics due to improved affordability and wider awareness.
“Earlier, most patients were from tier 1 hospitals. Now we are getting samples from Jammu & Kashmir, Rajasthan, and many tier 2 and 3 cities,” Goswami explained.
To make genomic testing more accessible, 4baseCare has worked on reducing costs significantly. Some of its earlier offerings were priced at nearly one-fourth the cost of competing solutions. Looking ahead, the company aims to integrate genomic testing into public healthcare initiatives such as Ayushman Bharat, making advanced cancer diagnostics available to a broader population.
A key component of the company’s growth strategy is its AI-powered OncoTwin platform. The technology utilizes multimodal datasets, including genomic, pathology, radiology, and clinical information, to create digital twins of cancer patients. By analyzing similar patient profiles and treatment outcomes, the platform helps physicians make more informed clinical decisions.
Clarifying the platform’s role, Rishi said, “We are not recommending treatment directly. We are giving doctors real-world evidence of what worked for similar patients across datasets.”
The participation of Infosys in the funding round reflects growing interest in AI-driven healthcare innovation. According to Goswami, the investment aligns with broader healthcare technology opportunities.
“It is mostly strategic in nature,” Goswami said. “Infosys realised that we are not just a diagnostics company. We are building AI solutions on top of healthcare datasets, and that aligns with larger healthcare and AI initiatives they are exploring with enterprise customers.”
Infosys has steadily expanded its healthcare technology portfolio through investments and acquisitions in healthcare data, digital health, and artificial intelligence-focused companies worldwide.
Financially, 4baseCare continues to demonstrate strong growth momentum. The company claims to have remained revenue-positive for the past five years and currently generates approximately Rs 40 crore in annual revenue. Management expects revenue to surpass Rs 100 crore within the next 12 to 18 months, driven by international expansion, increased testing volumes, and growing adoption of its AI-powered oncology solutions.
By expanding its global laboratory network, decentralizing genomic testing, and scaling its OncoTwin platform, the company aims to make personalized cancer treatment more accessible across underserved markets. With support from investors including Infosys and growX Ventures, 4baseCare is well-positioned to play a significant role in the future of AI-driven healthcare and precision medicine.
